Editas Medicine may have been first to enter the clinic with a gene-editing therapy, but it was beaten to the finish line by Intellia with first-in-human results in June. But it’s not a competition.
Prime Medicine reports new preclinical data demonstrating the ability of prime editors to efficiently and precisely correct the predominant mutations that cause rhodopsin-associated autosomal dominant ...
WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...
Shares in Wave Life Sciences rose by 74% after it reported clinical data with a pioneering new RNA-editing therapy for alpha-1 antitrypsin deficiency (AATD). Wave claims this is the first clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback